A weak Q1 for Novartis that was heavily impacted by generics erosion showcases that the billions of dollars being spent by the pharma industry to shore up revenue streams amid a looming patent cliff ...

Rocket Pharmaceuticals has signed an agreement to sell its rare paediatric disease PRV for $180m to advance its gene therapy pipeline.

Merck KGaA and Remepy will work in tandem to develop drug-digital therapy combinations for a rare cancer indication.

Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines.

Pharmaceutical trade associations across the Nordic region have reacted with vigilance to a recent GlobalData report that highlighted the potential effect on product launch and withdrawal trends in ...

Sun Pharma has signed a definitive agreement to acquire Organon in a transaction with an enterprise valuation of $11.75bn in cash.

BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, buying the company for $14.50 per share in an all-cash deal.

AstraZeneca has received approval from the FDA for the subcutaneous self-administration of Saphnelo using the Saphnelo pen for SLE.

With an uptick and increasingly even spread of capital across the space, the BIA’s Martin Turner is optimistic for British biotech’s future.

AI capabilities within pharma are evolving from add-on to an arm of core business demanding overhauled AI governance.

Ajax’s lead asset is AJ1-11095, a once-daily Type II JAK2 inhibitor taken orally, which is currently in a Phase I trial.

This White House deal will see Regeneron offer all its new medicines at “MFN prices”, while providing Otarmeni for free to eligible patients.